GSK's Hepatitis B Candidate Bepirovirsen Demonstrates Potential in Phase III Trials, Paving the Way for Functional Cure

Key Clinical Trial Results

GSK evaluated bepirovirsen in two Phase III studies named B-Well 1 and B-Well 2, which involved more than 1,800 CHB patients across 29 countries. The trials met the primary endpoint, demonstrating that in patients with baseline hepatitis B surface antigen (HBsAg) levels below 3,000 IU/ml, bepirovirsen combined with the current standard treatment of nucleos(t)ide analogues achieved a statistically significant and clinically meaningful increase in functional cure rates compared to standard treatment alone.

In both studies, "functional cure" was defined as the disappearance of HBsAg and undetectable HBV DNA for at least 24 weeks after the end of treatment. GSK noted that the results were statistically significant across all hierarchical endpoints, particularly showing a greater effect in the subgroup of patients with HBsAg levels below 1000 IU/ml. The studies "demonstrated an acceptable safety and tolerability profile, consistent with what has been reported in other studies." GSK plans to reserve the detailed data for presentation at upcoming academic conferences and intends to submit regulatory approval applications in the first quarter of this year.

Drug Mechanism and Strategic Significance

Bepirovirsen is a drug designed to effectively treat CHB by reducing hepatitis B virus replication, inhibiting HBsAg, and stimulating the immune system. If successfully approved, bepirovirsen — the drug that GSK licensed from Ionis in 2019 for an upfront payment of $25 million — could become "the first limited, six-month treatment option for CHB and a cornerstone of future sequential treatment strategies."

GSK Chief Scientific Officer Dr. Tony Wood stated, "Bepirovirsen has the potential to transform treatment goals for CHB patients by achieving significant functional cure rates—a first breakthrough for this disease." GSK terminated the development of another functional cure candidate (therapeutic vaccine GSK3528869) a year ago due to poor data. In addition to bepirovirsen, GSK has multiple assets in clinical development for CHB, including the siRNA drug GSK5637608 targeting the hepatitis B virus, the PAPD5/PAPD7 inhibitor GSK3965193, and the TLR8 agonist GSK5251738.

Prospect

The success of Bepirovirsen in Phase III trials marks a crucial step forward in the global pursuit of a functional cure for hepatitis B. If its finite treatment regimen is approved, it will significantly reduce the burden of long-term treatment and monitoring for patients and may alter the natural course of the disease. The industry will closely monitor its regulatory review progress and its potential as a cornerstone of combination therapies, bringing new hope for ultimately overcoming chronic hepatitis B.